1.09
price up icon1.87%   0.02
after-market アフターアワーズ: 1.14 0.05 +4.59%
loading
前日終値:
$1.07
開ける:
$1.09
24時間の取引高:
1.67M
Relative Volume:
0.98
時価総額:
$124.92M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.6606
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
+18.30%
1か月 パフォーマンス:
-3.54%
6か月 パフォーマンス:
-23.24%
1年 パフォーマンス:
-67.85%
1日の値動き範囲:
Value
$1.08
$1.155
1週間の範囲:
Value
$0.91
$1.24
52週間の値動き範囲:
Value
$0.6611
$4.20

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1157)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2025-08-08
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

FATE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.09 123.40M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.79 100.07B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.41 59.99B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
448.91 58.03B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
653.83 39.93B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
321.36 36.82B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Aug 16, 2025

Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Live Scanner Shows Breakout on Fate Therapeutics Inc.Gold Moves & Technical Entry and Exit Alerts - metal.it

Aug 16, 2025
pulisher
Aug 15, 2025

BofA Securities Adjusts Fate Therapeutics Price Target to $2 From $2.20, Maintains Neutral Rating - MarketScreener

Aug 15, 2025
pulisher
Aug 15, 2025

Fate Therapeutics' Price Target Cut to $2.50 by Wells Fargo - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Barclays Maintains Buy Rating on Fate Therapeutics with $2.00 Price Target - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Is Now a Good Time to Reenter Fate Therapeutics Inc.Risk Management & Low Drawdown Momentum Trade Ideas - newsyoung.net

Aug 14, 2025
pulisher
Aug 14, 2025

Fate Therapeutics Announces Corporate Restructuring Plan - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Fate Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aug 14, 2025
pulisher
Aug 14, 2025

Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

Fate Therapeutics Reports Q2 2025 Financial Results - TipRanks

Aug 14, 2025
pulisher
Aug 13, 2025

Fate Therapeutics Inc. Bounces Off Moving Average SupportCPI Data & Long-Term Growth Stock Strategies - beatles.ru

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics shares rise 4.42% after-hours after reporting better-than-expected Q2 earnings. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics Soars 28% on Earnings Optimism and Strategic Shifts - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics shares surge 26.07% intraday after Q2 earnings beat expectations and cash runway extended to 2027. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

FATE's 24.4% Surge: Clinical Breakthroughs and Strategic Restructuring Ignite Biotech Volatility - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $2 to $6 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics: Q2 Earnings Snapshot - Greenwich Time

Aug 13, 2025
pulisher
Aug 13, 2025

Wells Fargo lowers Fate Therapeutics stock price target to $2.50 on cost cuts - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics 2025 Q2 Earnings Narrowed Losses but Revenue Falls Sharply - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire

Aug 13, 2025
pulisher
Aug 12, 2025

Bullish Divergence Spotted in Fate Therapeutics Inc. MomentumAccurate Buy Point for Momentum Stocks Detected - sundaytimes.kr

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics' Q2 2025 Earnings: A Strategic Catalyst for Long-Term Shareholder Value - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2025
pulisher
Aug 09, 2025

Can machine learning forecast Fate Therapeutics Inc. recoveryBuy Opportunity Forecast for Fast Traders - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

What makes Fate Therapeutics Inc. stock price move sharplyHigh Conviction Stock Long-Term Summary - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Trade Opportunity Alerts - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Analyzing net buyer seller activity in Fate Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Fate Therapeutics Inc. stock trend forecastFree Risk Controlled Picks With Real Returns - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Fate Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalWatchlist for Smart Swing Trading Updated - metal.it

Aug 07, 2025
pulisher
Aug 07, 2025

Fate Therapeutics shares fall 4.52% intraday due to unspecified reasons. - AInvest

Aug 07, 2025
pulisher
Aug 06, 2025

Full technical analysis of Fate Therapeutics Inc. stockSwing Trade Picks with High Potential - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Fate Therapeutics shares fall 4.17% intraday after granting non-qualified stock options to a new employee. - AInvest

Aug 06, 2025
pulisher
Aug 05, 2025

Fate Therapeutics CEO Makes a Notable Stock Sale! - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics' Strategic Talent Acquisition and Equity Incentive Program: A Catalyst for Biotech Innovation and Shareholder Value - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics reports new employee inducement awards - MarketScreener

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics CEO Valamehr sells $15,396 in stock By Investing.com - Investing.com Nigeria

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics CEO Valamehr sells $15,396 in stock - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Cwm LLC Buys 37,290 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Aug 05, 2025
pulisher
Aug 05, 2025

Fate Therapeutics (NASDAQ:FATE) Upgraded at Wall Street Zen - Defense World

Aug 05, 2025
pulisher
Aug 04, 2025

Fate Therapeutics Inc. Nearing Breakout Level After BounceAccurate Technical Trend Reversal Picks Detected - metal.it

Aug 04, 2025
pulisher
Aug 03, 2025

What catalysts could drive Fate Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Fate Therapeutics Inc. stockFree Stock Market Return Analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is Fate Therapeutics Inc. company’s balance sheetFree Capital Efficiency Planning - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Fate Therapeutics Inc. in the next 12 monthsDiscover the next big stock winners - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Fate Therapeutics Inc. generate profit in a changing economyFree Stock Market Trend Analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Wells Fargo Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $4 - 富途牛牛

Aug 03, 2025
pulisher
Aug 03, 2025

What is Fate Therapeutics Inc. company’s growth strategyUnlock exclusive stock market insights - Jammu Links News

Aug 03, 2025

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$36.35
price down icon 0.41%
$86.92
price up icon 0.88%
$26.69
price up icon 0.91%
$127.80
price up icon 0.04%
$113.52
price up icon 0.73%
biotechnology ONC
$321.36
price up icon 3.77%
大文字化:     |  ボリューム (24 時間):